Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Retained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Contineum Therapeutics (CTNM) Total Liabilities (2023 - 2026)

Contineum Therapeutics' Total Liabilities history spans 4 years, with the latest figure at $11.3 million for Q1 2026.

  • Quarterly Total Liabilities fell 16.21% to $11.3 million in Q1 2026 from the year-ago period, while the trailing twelve-month figure was $11.3 million through Mar 2026, down 16.21% year-over-year, with the annual reading at $15.7 million for FY2025, 5.9% up from the prior year.
  • Total Liabilities came in at $11.3 million for Q1 2026, down from $15.7 million in the prior quarter.
  • In the past five years, Total Liabilities ranged from a high of $97.5 million in Q1 2023 to a low of $3.9 million in Q2 2024.
  • The 4-year median for Total Liabilities is $11.5 million (2025), against an average of $24.1 million.
  • Year-over-year, Total Liabilities tumbled 93.26% in 2024 and then soared 198.49% in 2025.
  • Contineum Therapeutics' Total Liabilities stood at $5.7 million in 2023, then skyrocketed by 159.22% to $14.8 million in 2024, then rose by 5.9% to $15.7 million in 2025, then decreased by 27.76% to $11.3 million in 2026.
  • Per Business Quant, the three most recent readings for CTNM's Total Liabilities are $11.3 million (Q1 2026), $15.7 million (Q4 2025), and $10.4 million (Q3 2025).